Synthetic Tripeptide Bioregulator

Cartalax 20mg

A synthetic tripeptide analogue (Ala-Glu-Asp). This short amino acid sequence (C₁₂H₁₉N₃O₈) is widely researched for its potent regenerative properties in cartilage, bone, and connective tissues.

Molecular Engineering Data

Molecular FormulaC₁₂H₁₉N₃O₈

Molecular Weight333.29 g/mol

SequenceAla-Glu-Asp (AED)

Physical StateLyophilised Solid

Primary MechanismChondrocyte Proliferation

Assay (HPLC)>99.0% Purity

Tissue Regeneration Cascade

Cartalax represents a targeted approach in musculoskeletal peptide research. It functions by heavily stimulating the proliferation of chondrocytes and fibroblasts. This pathway allows researchers to observe enhanced tissue repair and protection against degenerative joint processes, bypassing the systemic side effects associated with traditional anti-inflammatory compounds.

ECM
Cartilage Matrix Synthesis

Observed to elevate the production of extracellular matrix components, fundamentally supporting joint elasticity and mitigating structural degradation.

FGF
Fibroblast Activation

Enhances the cellular signaling necessary for fibroblast proliferation, creating an optimal environment for tendon, ligament, and connective tissue healing.

Structural Blueprint

The 333.29 Da structure (Ala-Glu-Asp) is designed to mimic naturally occurring peptide bioregulators found in healthy cartilage. The highly specific tripeptide sequence allows for exceptional tissue targeting and efficient cellular uptake, ensuring it interacts directly at the site of joint degradation.

Cartalax Structure

Pharmacological Benchmarks

Base Origin: Synthetic Khavinson Bioregulator
Primary Action: Fibroblast & Chondrocyte Proliferation
Tissue Target: Cartilage, Spine & Connective Tissue
Systemic Toxicity: None Observed
Application: Osteoarthritis & Musculoskeletal Trauma Models

Key Research Benchmarks

In preclinical models, Cartalax is extensively investigated for its targeted effects on Osteoarthritis Modeling and Connective Tissue Trauma. Researchers map the synthesis rates of collagen and proteoglycans to determine its volumetric efficacy in restoring joint mobility and combating structural decline.

Joint Restoration
Observing the marked increase in cartilage thickness and shock-absorption capacity under rigorous degenerative modeling.

Anti-Degenerative Action
Analysis of cellular senescence mitigation and the preservation of synovial fluid quality following induced mechanical stress.

Laboratory Protocol & Handling

Storage & Stability
Supplied lyophilised for maximum sequence integrity during logistics.

Dry Storage: -20°C for >12 months; 2-8°C for <6 months.
Liquid Stability: Must be refrigerated (2-8°C) once reconstituted.
Solubility: Water (1mg/ml) or sterile physiological saline.

Reconstitution SOP
Strict adherence to laboratory SOPs is required to maintain the tripeptide chain.

Solvent: Sterile Bacteriostatic Water or PBS.
Technique: Slow sidewall induction; do not agitate the puck.
Unit Sizes: 20mg precision research configurations.

Strict Laboratory Compliance Notice

WARNING: This compound is a chemical reagent supplied exclusively for in-vitro and in-vivo laboratory research. It is NOT a drug, medication, or food supplement. Strictly prohibited for human or veterinary administration. Lawful handling is the sole responsibility of the professional user. HRS Distribution assumes no liability for applications outside of laboratory scientific research.